EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSOMYG00000029423
Gene Symbol: PIK3R5
1 Cross references
179 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSOMYG00000045841
Gene Symbol: PIK3R5
1 Cross references
194 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSOMYG00000033090
Gene Symbol: PIK3R5
1 Cross references
193 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 2 (Beta)

Ensembl ID : ENSOMYG00000001470
Gene Symbol: PIK3R2
1 Cross references
183 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 2 (Beta)

Ensembl ID : ENSOMYG00000046863
Gene Symbol: PIK3R2
1 Cross references
183 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 3b (Gamma)

Ensembl ID : ENSOMYG00000007606
Gene Symbol: PIK3R3B
1 Cross references
155 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSOMYG00000016356
Gene Symbol: PLA2G10
1 Cross references
225 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSOMYG00000014469
Gene Symbol: PLA2G10
1 Cross references
226 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSOMYG00000012015
Gene Symbol: GART
1 Cross references
239 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSOMYG00000039007
Gene Symbol: GART
1 Cross references
240 Possible Orthologues:

Plasminogen

Ensembl ID : ENSOMYG00000046832
Gene Symbol: PLG
1 Cross references
250 Possible Orthologues:

Plasminogen

Ensembl ID : ENSOMYG00000005993
Gene Symbol: PLG
2 Cross references
250 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).